

Corporate Update

Vancouver, BC, Canada, November 18, 2013 – Auxellence Health Corporation (CNSX:AID) (the "Company" or "Auxellence") is pleased to announce that the hardware component of the TULIP(TM) system has been completed on schedule. Auxellence has been shipped a manufacturing prototype device for market testing. The software component is currently in beta testing, in preparation for regulatory approvals.

Contact:

Sydney Au, President & CEO Auxellence Health Corporation Email: sydau945@gmail.com

Phone: (604) 780-3311

About Auxellence Health Corporation

Auxellence is a health technology company that aims to provide high-level online services to consumers, providers and suppliers of health care products and services, including refining the effectiveness of prescribing services to the Over-The-Counter (OTC) consumer and natural health industry. Integrating innovative therapeutic and diagnostic (theragnostic) devices (hardware components), along with an interactive Expert System and Recommender "PRESCRIPTOR" engine (software platform) the system acquires physiological data to offer personalized health solutions to everyday common health issues (initially targeting weight management and skin health-acne).

Disclaimer for Forward-Looking Information Statements in this press release regarding the Company which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Such information can generally be identified by the use of forwarding-looking wording such as "may", "will", "expect", "estimate", "anticipate", "intend", "believe" and "continue" or the negative thereof or similar variations. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated in such statements due to factors. Except as required by law, the Company does not intend to update any changes to such statements. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither CNSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CNSX) accepts responsibility for the adequacy or accuracy of this release.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES